blood cancer Archive — Page 1 of 6
-
June 23, 2025
Low blood cell counts drive cancer in explosive blood disorder: study
The analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at VUMC was published in eClinicalMedicine. -
November 25, 2024
Potential treatment eyed for abnormal blood cell disorder
Research could lead to improved diagnosis and the first effective treatment for the disorder, called “clonal hematopoiesis of indeterminate potential,” or CHIP. -
November 4, 2024
Tae Kon Kim receives V Foundation grant for MDS drug research
Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS. -
June 4, 2024
Research raises hope for treating potentially lethal blood condition
Roughly 1 in 10 people over age 70 will develop CHIP, an explosive, clonal growth of abnormal blood cells that increases risk of blood cancers and death from cardiovascular, lung and liver disease. -
April 24, 2024
VUMC hosts symposium on stem cell transplants and cellular therapies
The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease. -
March 28, 2024
Study identifies molecule as potential target for treating AML
While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. -
January 4, 2024
Potential AML therapy induces leukemic stem cell death
Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.